372 related articles for article (PubMed ID: 33481339)
1. Immune cell infiltrates as prognostic biomarkers in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis.
McGuigan AJ; Coleman HG; McCain RS; Kelly PJ; Johnston DI; Taylor MA; Turkington RC
J Pathol Clin Res; 2021 Mar; 7(2):99-112. PubMed ID: 33481339
[TBL] [Abstract][Full Text] [Related]
2. Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers.
Knudsen ES; Vail P; Balaji U; Ngo H; Botros IW; Makarov V; Riaz N; Balachandran V; Leach S; Thompson DM; Chan TA; Witkiewicz AK
Clin Cancer Res; 2017 Aug; 23(15):4429-4440. PubMed ID: 28348045
[No Abstract] [Full Text] [Related]
3. The prognostic value of tumour-infiltrating lymphocytes in pancreatic cancer: a systematic review and meta-analysis.
Orhan A; Vogelsang RP; Andersen MB; Madsen MT; Hölmich ER; Raskov H; Gögenur I
Eur J Cancer; 2020 Jun; 132():71-84. PubMed ID: 32334338
[TBL] [Abstract][Full Text] [Related]
4. The Importance of a Conjoint Analysis of Tumor-Associated Macrophages and Immune Checkpoints in Pancreatic Cancer.
Xu JY; Wang WS; Zhou J; Liu CY; Shi JL; Lu PH; Ding JL
Pancreas; 2019 Aug; 48(7):904-912. PubMed ID: 31268976
[TBL] [Abstract][Full Text] [Related]
5. PD-1, PD-L1, and CD163 in pancreatic undifferentiated carcinoma with osteoclast-like giant cells: expression patterns and clinical implications.
Luchini C; Cros J; Pea A; Pilati C; Veronese N; Rusev B; Capelli P; Mafficini A; Nottegar A; Brosens LAA; Noë M; Offerhaus GJA; Chianchiano P; Riva G; Piccoli P; Parolini C; Malleo G; Lawlor RT; Corbo V; Sperandio N; Barbareschi M; Fassan M; Cheng L; Wood LD; Scarpa A
Hum Pathol; 2018 Nov; 81():157-165. PubMed ID: 30031096
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value, localization and correlation of PD-1/PD-L1, CD8 and FOXP3 with the desmoplastic stroma in pancreatic ductal adenocarcinoma.
Diana A; Wang LM; D'Costa Z; Allen P; Azad A; Silva MA; Soonawalla Z; Liu S; McKenna WG; Muschel RJ; Fokas E
Oncotarget; 2016 Jul; 7(27):40992-41004. PubMed ID: 27329602
[TBL] [Abstract][Full Text] [Related]
7. Programmed Cell Death Ligand-1 (PD-L1) and CD8 Expression Profiling Identify an Immunologic Subtype of Pancreatic Ductal Adenocarcinomas with Favorable Survival.
Danilova L; Ho WJ; Zhu Q; Vithayathil T; De Jesus-Acosta A; Azad NS; Laheru DA; Fertig EJ; Anders R; Jaffee EM; Yarchoan M
Cancer Immunol Res; 2019 Jun; 7(6):886-895. PubMed ID: 31043417
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 expression in pancreatic ductal adenocarcinoma is a poor prognostic factor in patients with high CD8
Yamaki S; Yanagimoto H; Tsuta K; Ryota H; Kon M
Int J Clin Oncol; 2017 Aug; 22(4):726-733. PubMed ID: 28314962
[TBL] [Abstract][Full Text] [Related]
9. The clinicopathological and prognostic significance of PD-L1 expression in pancreatic cancer: A meta-analysis.
Gao HL; Liu L; Qi ZH; Xu HX; Wang WQ; Wu CT; Zhang SR; Xu JZ; Ni QX; Yu XJ
Hepatobiliary Pancreat Dis Int; 2018 Apr; 17(2):95-100. PubMed ID: 29576277
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Implications of Intratumoral and Peritumoral Infiltrating Lymphocytes in Pancreatic Ductal Adenocarcinoma.
Pyo JS; Son BK; Lee HY; Oh IH; Chung KH
Curr Oncol; 2021 Nov; 28(6):4367-4376. PubMed ID: 34898543
[TBL] [Abstract][Full Text] [Related]
11. Immunologic and Metabolic Features of Pancreatic Ductal Adenocarcinoma Define Prognostic Subtypes of Disease.
Hutcheson J; Balaji U; Porembka MR; Wachsmann MB; McCue PA; Knudsen ES; Witkiewicz AK
Clin Cancer Res; 2016 Jul; 22(14):3606-17. PubMed ID: 26858311
[TBL] [Abstract][Full Text] [Related]
12. The M2 phenotype of tumor-associated macrophages in the stroma confers a poor prognosis in pancreatic cancer.
Hu H; Hang JJ; Han T; Zhuo M; Jiao F; Wang LW
Tumour Biol; 2016 Jul; 37(7):8657-64. PubMed ID: 26738860
[TBL] [Abstract][Full Text] [Related]
13. Developing an enhanced 7-color multiplex IHC protocol to dissect immune infiltration in human cancers.
Sun Z; Nyberg R; Wu Y; Bernard B; Redmond WL
PLoS One; 2021; 16(2):e0247238. PubMed ID: 33596250
[TBL] [Abstract][Full Text] [Related]
14. Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma.
Tessier-Cloutier B; Kalloger SE; Al-Kandari M; Milne K; Gao D; Nelson BH; Renouf DJ; Sheffield BS; Schaeffer DF
BMC Cancer; 2017 Sep; 17(1):618. PubMed ID: 28870260
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of cancer stem cell marker CD133 expression in pancreatic ductal adenocarcinoma (PDAC): a systematic review and meta-analysis.
Li X; Zhao H; Gu J; Zheng L
Int J Clin Exp Pathol; 2015; 8(10):12084-92. PubMed ID: 26722393
[TBL] [Abstract][Full Text] [Related]
16. Prognostic role and correlation of CA9, CD31, CD68 and CD20 with the desmoplastic stroma in pancreatic ductal adenocarcinoma.
Diana A; Wang LM; D'Costa Z; Azad A; Silva MA; Soonawalla Z; Allen P; Liu S; McKenna WG; Muschel RJ; Fokas E
Oncotarget; 2016 Nov; 7(45):72819-72832. PubMed ID: 27637082
[TBL] [Abstract][Full Text] [Related]
17. [Pathological features related to onco-immunity and their clinical significance of pancreatic ductal adenocarcinoma].
Wang CM; Xu CY; Jiang S; Zhou Q; Jiang ZJ; Cheng GP; Wu MJ; Feng TT; Yin WJ
Zhonghua Bing Li Xue Za Zhi; 2022 May; 51(5):419-424. PubMed ID: 35511637
[No Abstract] [Full Text] [Related]
18. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
Yang WF; Wong MCM; Thomson PJ; Li KY; Su YX
Oral Oncol; 2018 Nov; 86():81-90. PubMed ID: 30409325
[TBL] [Abstract][Full Text] [Related]
19. Comparative characterization of stroma cells and ductal epithelium in chronic pancreatitis and pancreatic ductal adenocarcinoma.
Helm O; Mennrich R; Petrick D; Goebel L; Freitag-Wolf S; Röder C; Kalthoff H; Röcken C; Sipos B; Kabelitz D; Schäfer H; Oberg HH; Wesch D; Sebens S
PLoS One; 2014; 9(5):e94357. PubMed ID: 24797069
[TBL] [Abstract][Full Text] [Related]
20. Unraveling the potential of CD8, CD68, and VISTA as diagnostic and prognostic markers in patients with pancreatic ductal adenocarcinoma.
Rezagholizadeh F; Tajik F; Talebi M; Taha SR; Shariat Zadeh M; Farhangnia P; Hosseini HS; Nazari A; Mollazadeh Ghomi S; Kamrani Mousavi SM; Haeri Moghaddam N; Khorramdelazad H; Joghataei MT; Safari E
Front Immunol; 2024; 15():1283364. PubMed ID: 38357542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]